Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency

Phase 4

Terminated

Conditions: Adult Growth Hormone Deficiency
Growth Hormone Disorder

Interventions: Drug: somatropin

First Posted Date: 2012-10-03

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7

Registration Number: NCT01698944

Locations: 🇬🇷
Novo Nordisk Investigational Site, Athens, Greece

Efficacy of Repaglinide in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide
Drug: glyburide
Drug: placebo

First Posted Date: 2012-10-03

Last Posted Date: 2017-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 9

Registration Number: NCT01698931

Locations: 🇮🇹
Novo Nordisk Investigational Site, Padova, Italy

Comparison of Two Insulin Aspart Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: insulin aspart

First Posted Date: 2012-10-03

Last Posted Date: 2017-03-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01698697

Locations: 🇿🇦
Novo Nordisk Investigational Site, Bloemfontein, South Africa

Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin NPH
Drug: insulin detemir
Drug: insulin aspart

First Posted Date: 2012-10-02

Last Posted Date: 2017-01-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 131

Registration Number: NCT01697657

Locations: 🇸🇪
Novo Nordisk Investigational Site, Trelleborg, Sweden

Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30
Drug: biphasic human insulin 30

First Posted Date: 2012-10-02

Last Posted Date: 2017-01-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 13

Registration Number: NCT01697618

Locations: 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom

Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation

Phase 4

Completed

Conditions: Foetal Growth Problem
Small for Gestational Age

Interventions: Drug: somatropin

First Posted Date: 2012-10-02

Last Posted Date: 2017-01-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 75

Registration Number: NCT01697644

Locations: 🇳🇱
Novo Nordisk Investigational Site, Rotterdam, Netherlands

Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30
Drug: insulin aspart

First Posted Date: 2012-10-02

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 131

Registration Number: NCT01697631

Locations: 🇵🇱
Novo Nordisk Investigational Site, Wroclaw, Poland

An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes
Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2012-09-28

Last Posted Date: 2018-12-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 29304

Registration Number: NCT01696266

Locations: 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden

Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2012-09-26

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 15

Registration Number: NCT01692925

Locations: 🇪🇸
Novo Nordisk Investigational Site, Madrid, Spain

Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Healthy
Diabetes

Interventions: Drug: NNC0113-0987
Drug: placebo

First Posted Date: 2012-09-21

Last Posted Date: 2017-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 45

Registration Number: NCT01690169

Locations: 🇬🇧
Novo Nordisk Investigational Site, Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy